Zacks Investment Research | Apr 07, 2021 03:13AM ET
The biotech sector continues to be in focus as the development of vaccines for coronavirus continues to be the key focus. Other pipeline and regulatory updates also grabbed the spotlight.
Recap of the Week’s Most Important Stories:
Acadia Plunges on CRL: Shares of Acadia Pharmaceuticals, Inc. GILD Kite announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for chimeric antigen receptor (CAR) T-cell therapy, Tecartus (brexucabtagene autoleucel). The sBLA is seeking approval of the therapy for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The sBLA is supported by the data from the phase I/II ZUMA-3 trial. Tecartus was granted accelerated approval in July 2020 by the FDA for the treatment of relapsed or refractory mantle cell lymphoma, based on the overall response rate and durability of response.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.